CellCarta Executive and Leadership Team

Dusty Tenney, the Chief Executive Officer at CellCarta, directs the overarching corporate strategy and operational execution. Tenney guides the organization's mission to provide comprehensive biomarker platforms and services, directly impacting the advancement of precision medicine for the biopharmaceutical industry. This leadership role involves fostering innovation across all departments, ensuring CellCarta addresses the most complex scientific testing needs for its partners. By setting the strategic vision, Dusty Tenney ensures the company remains at the forefront of biomarker research and development, driving growth and solidifying its position as a leading Contract Research Organization Laboratory (CRO). The CEO's focus extends to cultivating key industry relationships and expanding market reach globally, aligning all functions toward delivering customized biomarker testing solutions that unlock the full potential of personalized healthcare.

Elliott Miller, the Chief Financial Officer at CellCarta, manages the company's financial planning, reporting, and fiscal strategy. Miller oversees all aspects of financial operations, ensuring robust fiscal health to support CellCarta's growth as a global Contract Research Organization Laboratory (CRO). This includes managing budgets, optimizing resource allocation, and developing financial models that align with the company's mission of advancing precision medicine through biomarker services. Elliott Miller's role is crucial in providing financial insights that inform strategic decision-making, particularly concerning investments in new biomarker platforms and scientific testing capabilities. By maintaining stringent financial controls and driving fiscal discipline, Miller ensures that CellCarta can effectively address complex scientific challenges and deliver customized solutions to its biopharmaceutical partners. The CFO's oversight is vital for sustainable operations and expansion.

Anthony Mattacchione, the Global Chief Financial Officer at CellCarta, directs the comprehensive financial operations and strategic fiscal planning across all international markets. Mattacchione is responsible for ensuring the financial integrity and sustainability of CellCarta's global Contract Research Organization Laboratory (CRO) services, supporting its mission to advance precision medicine. This involves overseeing global accounting practices, managing international tax strategies, and optimizing capital allocation to support the expansion of biomarker platforms and services worldwide. Anthony Mattacchione's leadership ensures that financial resources are effectively deployed to meet the complex scientific testing needs of biopharmaceutical clients across diverse regions. By providing critical financial oversight and strategic guidance, Mattacchione enables CellCarta to navigate global economic landscapes and maintain its commitment to delivering customized biomarker testing solutions that drive scientific innovation.

Louis Norton, the Chief Information Officer at CellCarta, architects and oversees the company's entire technology infrastructure and digital strategy. Norton ensures that all information systems support CellCarta's core mission of delivering advanced biomarker platforms and services to the biopharmaceutical sector. This involves managing data security, optimizing laboratory information management systems (LIMS), and implementing cutting-edge digital tools to enhance operational efficiency and scientific output. Louis Norton's responsibilities include driving the integration of new technologies that support the complex testing needs inherent in precision medicine research. By maintaining robust and scalable IT solutions, Norton directly enables the seamless execution of biomarker testing, ensuring data integrity and accessibility for clients. The CIO's strategic direction is critical for maintaining CellCarta's competitive edge in a data-intensive scientific landscape.

Ehab ElGabry, the Chief Medical Officer at CellCarta, provides critical medical and scientific leadership, guiding the company's biomarker strategy and clinical relevance. ElGabry ensures that CellCarta's extensive offering of biomarker platforms and services directly supports the advancement of precision medicine for the biopharmaceutical industry. This involves translating complex scientific findings into actionable insights for clients and overseeing the scientific rigor of all testing solutions. Ehab ElGabry's expertise is essential in addressing the most challenging scientific testing needs, ensuring the clinical utility and impact of customized biomarker solutions. By bridging the gap between laboratory science and clinical application, ElGabry drives innovation and reinforces CellCarta's position as a trusted partner in developing personalized healthcare approaches. The CMO's vision is integral to the scientific direction and market impact of the organization.